Based on the key indicators related to Coeptis Therapeutics' liquidity, profitability, solvency, and operating efficiency, Coeptis Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Coeptis Therapeutics' Intangible Assets are relatively stable compared to the past year. As of 01/22/2025, Common Stock is likely to grow to 4,034, though Net Debt is likely to grow to (232.7 K). Key indicators impacting Coeptis Therapeutics' financial strength include:
Investors should never underestimate Coeptis Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Coeptis Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Coeptis Therapeutics.
Net Income
(22.33 Million)
Coeptis
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Change To Inventory
Net Borrowings
Total Cashflows From Investing Activities
Depreciation
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Other Non Cash Items
Stock Based Compensation
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Net Tangible Assets
Other Assets
Property Plant Equipment
Other Current Liab
Non Currrent Assets Other
Net Receivables
Property Plant And Equipment Net
Non Current Liabilities Total
Capital Lease Obligations
Net Invested Capital
Property Plant And Equipment Gross
Short Long Term Debt
Capital Stock
Net Working Capital
Depreciation And Amortization
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Net Income Applicable To Common Shares
Net Interest Income
Selling General Administrative
Selling And Marketing Expenses
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Coeptis Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Coeptis Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Coeptis Therapeutics' assets may result in an increase in income on the income statement.
Coeptis Therapeutics competes with LMF Acquisition, ZyVersa Therapeutics, Sonnet Biotherapeutics, Revelation Biosciences, and Clearmind Medicine. Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania. Coeptis Therapeutics is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Coeptis Therapeutics's current stock value. Our valuation model uses many indicators to compare Coeptis Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Coeptis Therapeutics competition to find correlations between indicators driving Coeptis Therapeutics's intrinsic value. More Info.
Coeptis Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Coeptis Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Coeptis Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Coeptis Therapeutics Systematic Risk
Coeptis Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Coeptis Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Coeptis Therapeutics correlated with the market. If Beta is less than 0 Coeptis Therapeutics generally moves in the opposite direction as compared to the market. If Coeptis Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Coeptis Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Coeptis Therapeutics is generally in the same direction as the market. If Beta > 1 Coeptis Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Coeptis Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Coeptis Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Coeptis Therapeutics growth as a starting point in their analysis.
Coeptis Therapeutics January 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Coeptis Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Coeptis Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Coeptis Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Coeptis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Coeptis Therapeutics's daily price indicators and compare them against related drivers.
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.